prof. MUDr. Dalibor Valík, Ph.D., DABCC
Department head, Department of Laboratory Methods
Correspondence Address:
Kamenice 753/5, 625 00 Brno
Phone: | +420 532 23 3948 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 115
2024
-
Emergency medicine pharmacotherapy compromises accuracy of plasma creatinine determination by enzyme-based methods: real-world clinical evidence and implications for clinical practice
Frontiers in Medicine, year: 2024, volume: 10, edition: January 2024, DOI
-
Personalized dendritic cell vaccine in multimodal individualized combination therapy improves survival in high-risk pediatric cancer patients
International journal of cancer, year: 2024, volume: 155, edition: 8, DOI
2023
-
CoVigi phase IV multicentric trial evaluating COVID-19 vaccination effectiveness, safety, and immune response dynamics: SARS-CoV-2-specific antibody and T-cell response focused on patients with gastrointestinal tumors
Year: 2023, type: Conference abstract
-
CZECRIN dětem - aneb příměstský tábor Juniorské akademie LF MU také na Farmakologickém ústavu
Year: 2023, type: Workshop
-
Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma-a review and prospects for the future
Frontiers in Cardiovascular Medicine, year: 2023, volume: 10, edition: August 2023, DOI
-
Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors
Scientific Reports, year: 2023, volume: 13, edition: 1, DOI
2022
-
Dynamika středního objemu erytrocytů (MCV) jako potenciálního biomarkeru compliance a terapeutické toxicity sunitinibu u onkologických pacientů
Year: 2022, type:
-
Imunitní odpověď na vakcinaci proti covid-19 -průběžné výsledky studie CoVigi
Year: 2022, type: Conference abstract
-
Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing
JCO PRECISION ONCOLOGY, year: 2022, volume: 6, edition: June 2022, DOI
-
Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial
Annals of Oncology, year: 2022, volume: 33, edition: 7, DOI